Novartis Pipeline

Benefiting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines. Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide. This table provides an overview of selected projects in development. Please note: the Novartis Pipeline data is updated quarterly.

Download the Novartis pipeline as of December 31, 2022 (PDF 0.1 MB)

Showing 152 results
  • SKO136
    ensovibep
    Coronavirus infection
    Global Health Phase 2 Multi-specific DARPin
    Lead Indication
  • SOK583
    aflibercept
    Ophthalmology
    Biosimilars Phase 3 2024 VEGF inhibitor
    Supplementary Indication
  • TIN816
    TIN816
    Acute kidney injury
    Cardio-renal Phase 2 ATP modulator
    Lead Indication
  • TNO155
    TNO155
    Solid tumors (combo)
    Solid Tumors Phase 1 SHP2 inhibitor
  • TNO155
    TNO155
    Solid tumors (single agent)
    Solid Tumors Phase 2 >=2026 SHP2 inhibitor
    Lead Indication
  • TQJ230
    pelacarsen
    Secondary prevention of cardiovascular events in patients with elevated levels of Lipoprotein(a) (CVRR-Lp(a))
    Cardio-renal Phase 3 2025 ASO targeting Lp(a)
    Lead Indication
  • VAY736
    ianalumab
    Sjoegren's syndrome
    Immunology Phase 3 >=2026 BAFF-R inhibitor
    Lead Indication
  • VAY736
    ianalumab
    Lupus Nephritis
    Immunology Phase 3 >=2026 BAFF-R inhibitor
    New Indication
  • VAY736
    ianalumab
    Autoimmune Hepatitis (AIH)
    Immunology Phase 2 >=2026 BAFF-R inhibitor
    New Indication
  • VAY736
    ianalumab
    Systemic lupus erythematosus (SLE)
    Immunology Phase 2 >=2026 BAFF-R inhibitor
    New Indication
  • VAY736
    ianalumab
    2L Immune Thrombocytopenia
    Hematology Phase 3 >=2026 BAFF-R inhibitor
    Lead Indication
  • VAY736
    ianalumab
    1L Immune Thrombocytopenia
    Hematology Phase 3 >=2026 BAFF-R inhibitor
  • VAY736
    ianalumab
    warm Autoimmune Hemolytic Anemia
    Hematology Phase 3 >=2026 BAFF-R inhibitor
  • VAY736
    ianalumab + ibrutinib
    Haematological malignancy (combo)
    Hematology Phase 1 BAFF-R inhibitor
  • VDT482
    tislelizumab
    1L Small Cell Lung Cancer
    Solid Tumors Phase 3 2024 PD1 Inhibitor (Anti-PD-1 monoclonal antibody)
    New Indication
  • VDT482
    tislelizumab
    Localized ESCC
    Solid Tumors Phase 3 2024 PD1 Inhibitor (Anti-PD-1 monoclonal antibody)
    New Indication
  • VDT482
    tislelizumab
    Adj/Neo adj. NSCLC
    Solid Tumors Phase 3 >=2026 PD1 Inhibitor (Anti-PD-1 monoclonal antibody)
    New Indication
  • VDT482
    tislelizumab
    1L Urothelial Cell Carcinoma
    Solid Tumors Phase 3 >=2026 PD1 Inhibitor (Anti-PD-1 monoclonal antibody)
    New Indication
  • VDT482
    tislelizumab
    1L Hepatocellular Carcinoma
    Solid Tumors Phase 3 2023 PD1 Inhibitor (Anti-PD-1 monoclonal antibody)
    New Indication
  • VDT482
    tislelizumab
    1L Gastric cancer
    Solid Tumors Phase 3 2023 PD1 Inhibitor (Anti-PD-1 monoclonal antibody)
    New Indication
Legend

Combination abbreviations:
fulv    fulvestrant
tmx    tamoxifen
gsn    goserelin
NSAI  Non-steroidal aromatase inhibitor
Taf     Tafinlar® (dabrafenib)
Mek   Mekinist® (trametinib)

a    EU filing, approved in US.
b    US filing, approved in EU.
c    US filing, submitted in EU.
d    US pending submission, approved in EU
e    EU filing, submitted in US.

Disclaimer

This information was factually accurate on the date it was published. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date. For the latest information on the Novartis' pipeline, readers should visit the News and Investors sections of our website. This information constitutes forward-looking statements relating to Novartis AG's business, including express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products. Such forward-looking statements reflect the current views of Novartis AG regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that such products will achieve any particular revenue levels.

In particular, management's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; the Novartis Group's ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.